<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462942</url>
  </required_header>
  <id_info>
    <org_study_id>M/40464/30</org_study_id>
    <nct_id>NCT01462942</nct_id>
  </id_info>
  <brief_title>Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination</brief_title>
  <official_title>Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combinations Compared With Individual Components and Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to provide data supporting the use of LAS40464 as an efficacious and safe
      maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease
      (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase III study seeks to confirm the long-term bronchodilator efficacy and effects on
      COPD related health status and other secondary parameters as well as the safety of two doses
      of the combination of aclidinium bromide/formoterol FDC (FDC 400/12 μg and 400/6 μg) compared
      with aclidinium bromide monotherapy 400 μg, formoterol monotherapy 12 μg and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Transition Dyspnoea Index (TDI) Focal Score</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Evaluation of dyspnea was performed by an independent interviewer experienced in taking a respiratory history The TDI includes three categories: functional impairment which determines the impact of breathlessness on the ability to perform activities, magnitude of task which determines the type of task that caused breathlessness and magnitude of effort which establishes the level of effort needed to evoke breathlessness Each category ranges from minus three (-3; major deterioration) to plus three (+3; major improvement) including a zero (0) score to indicate 'no change' The three categories are totalled to obtain a focal score (total score) ranging from minus nine (-9), including zero (0), to plus nine (+9) Provision is made for circumstances when dyspnoea could not be rated - if reduction of activities, effort or functional impairment was caused by reasons other than respiratory A change of 1 unit in TDI is used as the criterion for a minimal meaningful improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in St. George´s Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>SGRQ is a standardised, self-administered tool for measuring impaired health and perceived well-being in respiratory diseases; a validated electronic version of the questionnaire in the relevant validated languages was used in this study The questionnaire contains 50 items divided into three dimensions (Symptoms, Activity and Impact) Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100: zero (0) score indicating no impairment of quality of life The total SGRQ score ranging from 0 to 100 is a summary score utilising responses to all items calculated using weights attached to each item of the questionnaire Higher scores indicate poorer health and change of 4 units in the SGRQ has been determined to be the threshold for a clinically relevant change in health status</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2443</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Aclidinium/Formoterol 400/6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 week, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidinium/Formoterol 400/12 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 week, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidinium monotherapy 400 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 week, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol monotherapy 12 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 week, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>24 week, double blind treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium Bromide/Formoterol Fumarate</intervention_name>
    <description>Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day</description>
    <arm_group_label>Aclidinium/Formoterol 400/6 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium Bromide/Formoterol Fumarate</intervention_name>
    <description>Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day</description>
    <arm_group_label>Aclidinium/Formoterol 400/12 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium Bromide</intervention_name>
    <description>Inhaled Aclidinium 400 μg, twice per day</description>
    <arm_group_label>Aclidinium monotherapy 400 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled dose-matched placebo, twice per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate</intervention_name>
    <description>Inhaled Formoterol 12 μg, twice per day</description>
    <arm_group_label>Formoterol monotherapy 12 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or non-pregnant, non-lactating female aged ≥40. Women of childbearing
             potential are allowed to enter the trial if they show to have a negative serum
             pregnancy test at the Screening Visit and are using, during the last two months before
             the Screening Visit, at least one medically approved and highly effective method of
             birth control defined as those which result in a low failure rate (i.e less than 1%
             per year) when used consistently and correctly such as implants, injectables, oral
             contraceptives combined with at least one barrier method, hormonal Intrauterine
             Devices (IUDs), sexual abstinence or vasectomy of the partner.

          -  Current or ex-cigarette smoker, with a smoking history of at least 10 pack-years.

          -  Patient with a clinical diagnosis of stable COPD according to the Global Initiative
             for Chronic Lung Disease &quot;GOLD&quot; Guidelines at the Screening Visit.

          -  Patient whose FEV1/FVC (Forced Vital Capacity) at the Screening Visit measured between
             10-15 minutes post inhalation of 400 micrograms of salbutamol is &lt; 70% (i.e., 100 x
             Post-salbutamol FEV1 /FVC &lt; 70%).

          -  Patient with a diagnosis of moderate to severe COPD according to the GOLD Guidelines
             classification (stages II and III) at the Screening Visit: FEV1 measured between 10-15
             minutes post inhalation of 400 micro grams of salbutamol is 30% &lt; FEV1 &lt; 80% of the
             predicted normal value (i.e., 100 x Post-salbutamol FEV1/ Predicted FEV1 must be &lt; 80%
             and ≥ 30%).

          -  Patient must be able to perform repeatable pulmonary function testing for FEV1
             according to American Thoracic Society/European Respiratory Society &quot;ATS/ERS&quot; 2005
             criteria at Screening Visit.

          -  Patient who is eligible and able to participate in the trial and who consent to do so
             in writing after the purpose and nature of the investigation have been explained.

        Exclusion Criteria:

          -  History or current diagnosis of asthma.

          -  Any respiratory tract infection (including the upper respiratory tract) or COPD
             exacerbation in the 6 weeks before Screening Visit.

          -  Patient hospitalised for COPD exacerbation within 3 months prior to Screening Visit.

          -  Clinically significant respiratory conditions defined as:

               -  Known active tuberculosis.

               -  History of interstitial lung or massive pulmonary thromboembolic disease.

               -  Pulmonary resection or lung volume reduction surgery within 12 months prior to
                  Screening Visit.

               -  History of lung transplantation.

               -  History of bronchiectasis secondary to respiratory diseases others than COPD
                  (e.g., cystic fibrosis, Kartagener's syndrome, etc).

               -  Known a1-antitrypsin deficiency.

          -  Patients who in the Investigator's opinion might have needed to start a pulmonary
             rehabilitation program during the study and/or patients who started/finished it within
             3 months prior to screening.

          -  Use of long-term oxygen therapy (≥ 15 hours/day).

          -  Patients who did not maintain regular day/night, waking/sleeping cycles including
             night shift workers (eg, history of sleep apnoea syndrome, any condition related to
             sleep disturbances such as restless-legs syndrome or somnambulism).

          -  Clinically significant cardiovascular conditions defined as:

               -  Myocardial infarction within the 6 months prior to screening.

               -  Thoracic surgery within 12 months prior to screening.

               -  Unstable angina or unstable arrhythmia which had required changes in the
                  pharmacological therapy or other intervention within 12 months prior to
                  screening, or newly diagnosed arrhythmia within the previous 3 months prior to
                  screening.

               -  Hospitalisation within 12 months prior to screening for heart failure functional
                  classes III (marked limitation of activity and only comfortable at rest) and IV
                  (need of complete rest, confinement to bed or chair, discomfort at any physical
                  activity and presence of symptoms at rest) as per the New York Heart Association.

          -  Patients (with or without pharmacological therapy) with resting systolic blood
             pressure (SBP)

             ≥200 mmHg, a resting diastolic blood pressure (DBP) ≥120 mmHg, or a resting heart rate
             ≥105 beats per minute (bpm) at screening and at Visit 1 prior to randomisation.

          -  Patients with interval corrected for heart rate &quot;QTc&quot; [calculated according to
             formulae (QTc=QT/RR1/2) &gt; 470 msec as indicated in the centralised reading report
             assessed at Screening Visit.

          -  Patients with clinically relevant abnormalities in the clinical laboratory tests, ECG
             parameters (other than QT interval corrected using Bazett's formula [QTcB]) or in the
             physical examination at screening, if the abnormality defined a disease state listed
             as exclusion criteria, except for those related to COPD.

          -  Patients with a history of hypersensitivity reactions to inhaled anticholinergics,
             sympathomimetic amines, or inhaled medication or any component thereof (including
             report of paradoxical bronchospasm). Patients with known narrow-angle glaucoma,
             symptomatic bladder neck obstruction or acute urinary retention.

          -  Patients with symptomatic non-stable prostate hypertrophy. (However, patients with
             well-controlled, stable, asymptomatic benign prostatic hypertrophy were not excluded).

          -  Patients with known uncontrolled history of infection with human immunodeficiency
             virus and/or active hepatitis.

          -  Current diagnosis of cancer other than basal or squamous cell skin cancer.

          -  Life expectancy of less than 1 year.

          -  Patients with any other serious or uncontrolled physical or mental dysfunction that,
             as judged by the Investigator, could have placed the patient at higher risk from
             his/her participation in the study, could have confounded the results of the study, or
             is likely to prevent the patient from complying with the requirements of the study, or
             completing the study.

          -  Patients with a history (within 2 years prior to screening) of drug and/or alcohol
             abuse that might have prevented study compliance based on the Investigator judgment.

          -  Patients unlikely to be cooperative (eg, take the medication, complete the Patient
             Diaries or attend the clinic at the required times).

          -  Patients unable to properly use a DPI or pMDI inhaler device or to perform spirometry
             measurements.

          -  Patients previously randomised in a study involving aclidinium bromide/formoterol FDC.

          -  Patients previously randomised in a study involving aclidinium bromide monotherapy
             except when participation finished at least 6 months before screening.

          -  Patients treated with any investigational drug within 30 days (or 6 half-lives,
             whichever is longer) prior to screening.

          -  Patients who intended to use any concomitant medication not permitted by this protocol
             or who had not undergone the required washout period for a particular prohibited
             medication.

          -  Patients unable to give consent, or patients of consenting age but under guardianship,
             or vulnerable patients.

          -  Patients employed, or relatives of employees at the study centre, Almirall or Forest
             Laboratories.

          -  Any other conditions that, in the Investigator's opinion, might have indicated the
             patient to be unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #16</name>
      <address>
        <city>Ostrava Hrabuvka</city>
        <zip>700 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Praha 5 - Radotin</city>
        <zip>153 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>Praha 5</city>
        <zip>155 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #15</name>
      <address>
        <city>Praha 6</city>
        <zip>163 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #14</name>
      <address>
        <city>Praha 8</city>
        <zip>18200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Strakonice</city>
        <zip>386 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Tabor</city>
        <zip>390 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Espoo</city>
        <zip>2740</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Marseille cedex 6</city>
        <zip>13291</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>Vieux Conde</city>
        <zip>59690</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #19</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #24</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #16</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #23</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #15</name>
      <address>
        <city>Dresden</city>
        <zip>1067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #13</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #33</name>
      <address>
        <city>Haltern in Westfalen</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #21</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #36</name>
      <address>
        <city>Hessen</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #32</name>
      <address>
        <city>Land Niedersachsen</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #20</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #34</name>
      <address>
        <city>Muenchen</city>
        <zip>80539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #18</name>
      <address>
        <city>Nuernberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #22</name>
      <address>
        <city>Reinfeld</city>
        <zip>23858</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #35</name>
      <address>
        <city>Sachsen</city>
        <zip>1067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #27</name>
      <address>
        <city>Sachsen</city>
        <zip>2826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #28</name>
      <address>
        <city>Sachsen</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #25</name>
      <address>
        <city>Sachsen</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #16</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #17</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #14</name>
      <address>
        <city>Budapest</city>
        <zip>1221</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Budapest</city>
        <zip>1529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Komarom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Miskolc</city>
        <zip>3534</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #15</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #13</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Torokbalint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #15</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Buchon-si</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Seoul</city>
        <zip>137-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Breda</city>
        <zip>4811 VL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #13</name>
      <address>
        <city>Eindhoven</city>
        <zip>5632 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Leiderdorp</city>
        <zip>2352 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Rotterdam</city>
        <zip>3021 HC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Velp</city>
        <zip>6883 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Zoetermeer</city>
        <zip>2724 EK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #26</name>
      <address>
        <city>Bialystok</city>
        <zip>15-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #19</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-316</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #23</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #21</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Katowice</city>
        <zip>40-748</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #22</name>
      <address>
        <city>Katowice</city>
        <zip>40-751</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Krakow</city>
        <zip>31-024</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Krakow</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Lodz</city>
        <zip>92-216</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Lodz</city>
        <zip>93-319</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #14</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Poznan</city>
        <zip>60-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Poznan</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Poznan</city>
        <zip>60-823</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #13</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #18</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #15</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #16</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Brasov</city>
        <zip>500075</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Bucuresti</city>
        <zip>21382</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #18</name>
      <address>
        <city>Bucuresti</city>
        <zip>21659</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Bucuresti</city>
        <zip>30303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Bucuresti</city>
        <zip>50554</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #17</name>
      <address>
        <city>Constanta</city>
        <zip>900002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Constanta</city>
        <zip>900002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Deva</city>
        <zip>330084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Iasi</city>
        <zip>700115</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #16</name>
      <address>
        <city>Iasi</city>
        <zip>700381</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Targu Mures</city>
        <zip>RO540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Moscow</city>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Moscow</city>
        <zip>119620</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Bardejov</city>
        <zip>8501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Bratislava</city>
        <zip>821 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>5201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Sturovo</city>
        <zip>943 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Vysne Hagy</city>
        <zip>059 84</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Amanzimtoti</city>
        <zip>4126</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #15</name>
      <address>
        <city>Cape Town, Western Cape</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #16</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>Pretoria</city>
        <zip>2</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #13</name>
      <address>
        <city>Pretoria</city>
        <zip>2</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Pretoria</city>
        <zip>84</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Roodepoort</city>
        <zip>1724</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Somerset West</city>
        <zip>7129</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>Barcelona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Canet de Mar</city>
        <zip>8360</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Göteborg</city>
        <zip>41263</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Lund</city>
        <zip>22222</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Malmö</city>
        <zip>21152</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Vällingby</city>
        <zip>16268</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #18</name>
      <address>
        <city>Crimea Oblast</city>
        <zip>98603</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49051</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #9</name>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76012</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #17</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>Kharkov</city>
        <zip>61035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #15</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Kyiv</city>
        <zip>3680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #3</name>
      <address>
        <city>Kyiv</city>
        <zip>3680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Kyiv</city>
        <zip>3680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Kyiv</city>
        <zip>4050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Lugansk</city>
        <zip>91045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #6</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #12</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #10</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #13</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 5GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #5</name>
      <address>
        <city>Chorley</city>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #2</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #11</name>
      <address>
        <city>Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #14</name>
      <address>
        <city>Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #1</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #4</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #8</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #18</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #7</name>
      <address>
        <city>Reading</city>
        <zip>RG2 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #16</name>
      <address>
        <city>Stockton on Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #15</name>
      <address>
        <city>West midlands</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site #17</name>
      <address>
        <city>Wirral</city>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3970&amp;filename=M-40464-30-CSRsynopsis.pdf</url>
    <description>CSRsynopsis</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>October 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2011</study_first_posted>
  <results_first_submitted>September 14, 2016</results_first_submitted>
  <results_first_submitted_qc>December 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2017</results_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Bronchitis</keyword>
  <keyword>Chronic</keyword>
  <keyword>Emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 22 countries (Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, the Netherlands, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Ukraine and UK). The first patient was screened in October 2011 and the last patient visit was in January 2013</recruitment_details>
      <pre_assignment_details>In total, 2443 patients were screened, of whom 1729 were considered eligible and were randomized into the study. 714/2443 patients were not randomized due to screening failure (primarily for non-fulfillment of inclusion/exclusion criteria)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="P2">
          <title>Aclidinium/Formoterol 400/12 μg</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="P3">
          <title>Aclidinium/Formoterol 400/6 μg</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="P4">
          <title>Aclidinium 400 μg</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="P5">
          <title>Formoterol 12 μg</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="385"/>
                <participants group_id="P3" count="381"/>
                <participants group_id="P4" count="385"/>
                <participants group_id="P5" count="384"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="351"/>
                <participants group_id="P3" count="341"/>
                <participants group_id="P4" count="335"/>
                <participants group_id="P5" count="339"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, including COPD exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="B2">
          <title>Aclidinium/Formoterol 400/12 μg</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="B3">
          <title>Aclidinium/Formoterol 400/6 μg</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="B4">
          <title>Aclidinium 400 μg</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="B5">
          <title>Formoterol 12 μg</title>
          <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="194"/>
            <count group_id="B2" value="385"/>
            <count group_id="B3" value="381"/>
            <count group_id="B4" value="385"/>
            <count group_id="B5" value="384"/>
            <count group_id="B6" value="1729"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="8.0"/>
                    <measurement group_id="B2" value="62.7" spread="8.1"/>
                    <measurement group_id="B3" value="62.9" spread="7.7"/>
                    <measurement group_id="B4" value="63.1" spread="8.2"/>
                    <measurement group_id="B5" value="63.4" spread="7.8"/>
                    <measurement group_id="B6" value="63.2" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="129"/>
                    <measurement group_id="B6" value="560"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="256"/>
                    <measurement group_id="B5" value="255"/>
                    <measurement group_id="B6" value="1169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)</title>
        <time_frame>Baseline and Week 24</time_frame>
        <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/12 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium/Formoterol 400/6 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 400 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)</title>
          <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="339"/>
                <count group_id="O4" value="327"/>
                <count group_id="O5" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.030" spread="0.018"/>
                    <measurement group_id="O2" value="0.269" spread="0.013"/>
                    <measurement group_id="O3" value="0.213" spread="0.013"/>
                    <measurement group_id="O4" value="0.144" spread="0.013"/>
                    <measurement group_id="O5" value="0.129" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted by pre- and post-bronchodilator, age, and baseline FEV1 as covariates, and treatment group, sex, and smoking-status as fixed effect factors</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.125</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted by pre- and post-bronchodilator, age, and baseline FEV1 as covariates, and treatment group, sex, and smoking-status as fixed effect factors</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)</title>
        <time_frame>Baseline and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/12 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium/Formoterol 400/6 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 400 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)</title>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="349"/>
                <count group_id="O3" value="340"/>
                <count group_id="O4" value="332"/>
                <count group_id="O5" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.061" spread="0.018"/>
                    <measurement group_id="O2" value="0.083" spread="0.012"/>
                    <measurement group_id="O3" value="0.050" spread="0.012"/>
                    <measurement group_id="O4" value="0.056" spread="0.012"/>
                    <measurement group_id="O5" value="-0.002" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted by pre- and post-bronchodilator, age, and baseline FEV1 as covariates, and treatment group, sex, and smoking-status as fixed effect factors</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted by pre- and post-bronchodilator, age, and baseline FEV1 as covariates, and treatment group, sex, and smoking-status as fixed effect factors</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.053</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Transition Dyspnoea Index (TDI) Focal Score</title>
        <description>Evaluation of dyspnea was performed by an independent interviewer experienced in taking a respiratory history The TDI includes three categories: functional impairment which determines the impact of breathlessness on the ability to perform activities, magnitude of task which determines the type of task that caused breathlessness and magnitude of effort which establishes the level of effort needed to evoke breathlessness Each category ranges from minus three (-3; major deterioration) to plus three (+3; major improvement) including a zero (0) score to indicate 'no change' The three categories are totalled to obtain a focal score (total score) ranging from minus nine (-9), including zero (0), to plus nine (+9) Provision is made for circumstances when dyspnoea could not be rated - if reduction of activities, effort or functional impairment was caused by reasons other than respiratory A change of 1 unit in TDI is used as the criterion for a minimal meaningful improvement</description>
        <time_frame>Baseline and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/12 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium/Formoterol 400/6 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 400 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Transition Dyspnoea Index (TDI) Focal Score</title>
          <description>Evaluation of dyspnea was performed by an independent interviewer experienced in taking a respiratory history The TDI includes three categories: functional impairment which determines the impact of breathlessness on the ability to perform activities, magnitude of task which determines the type of task that caused breathlessness and magnitude of effort which establishes the level of effort needed to evoke breathlessness Each category ranges from minus three (-3; major deterioration) to plus three (+3; major improvement) including a zero (0) score to indicate 'no change' The three categories are totalled to obtain a focal score (total score) ranging from minus nine (-9), including zero (0), to plus nine (+9) Provision is made for circumstances when dyspnoea could not be rated - if reduction of activities, effort or functional impairment was caused by reasons other than respiratory A change of 1 unit in TDI is used as the criterion for a minimal meaningful improvement</description>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="344"/>
                <count group_id="O3" value="333"/>
                <count group_id="O4" value="331"/>
                <count group_id="O5" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.215" spread="0.241"/>
                    <measurement group_id="O2" value="2.508" spread="0.162"/>
                    <measurement group_id="O3" value="2.377" spread="0.165"/>
                    <measurement group_id="O4" value="2.112" spread="0.165"/>
                    <measurement group_id="O5" value="2.062" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted by BDI baseline score and age as covariates, with treatment group, gender, smoking-status, visit, and group-by-visit as fixed effect factors</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>1.293</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.728</ci_lower_limit>
            <ci_upper_limit>1.859</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted by BDI baseline score and age as covariates, with treatment group, gender, smoking-status, visit, and group-by-visit as fixed effect factors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.162</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.593</ci_lower_limit>
            <ci_upper_limit>1.730</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in St. George´s Respiratory Questionnaire (SGRQ) Total Score</title>
        <description>SGRQ is a standardised, self-administered tool for measuring impaired health and perceived well-being in respiratory diseases; a validated electronic version of the questionnaire in the relevant validated languages was used in this study The questionnaire contains 50 items divided into three dimensions (Symptoms, Activity and Impact) Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100: zero (0) score indicating no impairment of quality of life The total SGRQ score ranging from 0 to 100 is a summary score utilising responses to all items calculated using weights attached to each item of the questionnaire Higher scores indicate poorer health and change of 4 units in the SGRQ has been determined to be the threshold for a clinically relevant change in health status</description>
        <time_frame>Baseline and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/12 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium/Formoterol 400/6 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 400 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Administered BID by inhalation, in the mornings and evenings using a multi-dose dry powder inhaler (Genuair®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in St. George´s Respiratory Questionnaire (SGRQ) Total Score</title>
          <description>SGRQ is a standardised, self-administered tool for measuring impaired health and perceived well-being in respiratory diseases; a validated electronic version of the questionnaire in the relevant validated languages was used in this study The questionnaire contains 50 items divided into three dimensions (Symptoms, Activity and Impact) Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100: zero (0) score indicating no impairment of quality of life The total SGRQ score ranging from 0 to 100 is a summary score utilising responses to all items calculated using weights attached to each item of the questionnaire Higher scores indicate poorer health and change of 4 units in the SGRQ has been determined to be the threshold for a clinically relevant change in health status</description>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="332"/>
                <count group_id="O4" value="327"/>
                <count group_id="O5" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.511" spread="1.029"/>
                    <measurement group_id="O2" value="-7.164" spread="0.703"/>
                    <measurement group_id="O3" value="-8.339" spread="0.706"/>
                    <measurement group_id="O4" value="-5.801" spread="0.710"/>
                    <measurement group_id="O5" value="-5.579" spread="0.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5980</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted by SGRQ baseline score and age as covariates, with treatment group, gender, smoking-status, visit, and group-by-visit as fixed effect factors</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.653</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.082</ci_lower_limit>
            <ci_upper_limit>1.776</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1406</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted by SGRQ baseline score and age as covariates, with treatment group, gender, smoking-status, visit, and group-by-visit as fixed effect factors</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.828</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.259</ci_lower_limit>
            <ci_upper_limit>0.604</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>26 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Aclidinium/Formoterol 400/12 μg</title>
        </group>
        <group group_id="E3">
          <title>Aclidinium/Formoterol 400/6 μg</title>
        </group>
        <group group_id="E4">
          <title>Aclidinium 400 μg</title>
        </group>
        <group group_id="E5">
          <title>Formoterol 12 μg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis meckel's</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Episcleritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Allergic oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Traumatic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="385"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="94" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="105" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="384"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication and/or presentation whether complete or partial, of any part of the data or results of this trial will not be allowed until global publication and study results disclosure by the sponsor as per EUDRACT/FDA regulatory compliance obligations, and only after mutual agreement between the investigator and sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Esther Garcia</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

